Head-to-head · WeighScore
Spry vs Steady State Health
The verdict
Spry takes it — 56.8/100 to 54.9/100, but only just.
Spry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo). Steady State Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Spry | Steady State Health |
|---|---|---|
| WeighScore | 56.8/100 | 54.9/100 |
| Grade | C | C |
| Scorecard rank | #409 | #452 |
| Semaglutide | $199/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $299/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | 2 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #409 · C
Strengths
- Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
- Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
- Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
- No contracts or commitment required
- LegitScript Certified with a public verification link
Where it loses points
- Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
- Intake reviewed by a nurse practitioner, not an MD
- States served not disclosed publicly
- Pharmacy partner not named, and 503A vs 503B designation not specified
- FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Graded #452 · C
Strengths
- Prescribes semaglutide or tirzepatide within a perimenopause and menopause hormone-and-metabolic care plan
- Care delivered by a named women's-health nurse practitioner (Josie Cowburn, DNP, FNP-C)
- Transparent flat program fee from $139/mo, with a $99/mo standalone GLP-1 support option
Where it loses points
- Available only to Oregon and Washington residents
- GLP-1 medication is billed separately by the pharmacy and not included in the program fee
- Dispensing pharmacy is not publicly named
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.